The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicinVincenzo Quagliariello, Nicola Maurea, Michelino De Laurentiis et al.|Cardiovascular Diabetology|2021Cited by 368
Ranolazine Protects from Doxorubicin-Induced Oxidative Stress and Cardiac DysfunctionCarlo G. Tocchetti, Nicola Maurea, Andrea Carpi et al.|European Journal of Heart Failure|2014Cited by 92
Detection, Monitoring, and Management of Trastuzumab-Induced Left Ventricular Dysfunction: An Actual ChallengeCarlo G. Tocchetti, Nicola Maurea, Gianluca Ragone et al.|European Journal of Heart Failure|2012Cited by 88
Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical ModelsVincenzo Quagliariello, Nicola Maurea, Margherita Passariello et al.|Journal of Personalized Medicine|2020Cited by 68
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to TrastuzumabVincenzo Quagliariello, Nicola Maurea, Margherita Passariello et al.|International Journal of Cardiology|2019Cited by 64